



Jackson Hole Fire/EMS

Operations Manual

Approved by: Will Smith
Will Smith, MD, Medical Director

Approved by: Brady Hansen
Brady Hansen, Chief

Title: **Medication Protocol:
Tranexamic Acid**
Division: 17
Article: 1.34
Revised: March 2021
Pages: 1

Tranexamic Acid (TXA) (Medication Protocol)

PARAMEDIC PROVIDERS

STANDING ORDER

CLASS: Antifibrinolytic

PHARMACOLOGY/ ACTIONS: Competitively inhibits activation of plasminogen, reducing conversion of plasminogen to plasmin. At higher doses, directly inhibits plasmin activity. With massive bleeding, this may help stabilize clot formation and decrease extravascular bleeding.

ONSET/DURATION: Onset: 5-15 minutes / Duration: 3 hours

USE IN FIELD/ INDICATIONS:

- Penetrating wounds to **neck to mid-thigh (anterior, posterior, or both)** with anticipated significant blood loss.
- **Suspected** severe internal injuries from blunt trauma.
- Other causes of moderate to severe hemorrhagic shock **less than 3 hours old** with suspected need for transfusion due to internal or external blood loss.
 - Tachycardia- HR >110
 - Hypotension- SBP < 90 mmHg, Pedi < 70 + (age in yrs. x 2)

CONTRAINDICATIONS: Non-hemorrhagic shock and active intravascular clotting (DVT, PE).

SIDE EFFECTS: Impaired color vision, allergic reactions, thrombotic events, hypotension, nausea, vomiting, diarrhea.

ROUTE: IV/IO

DOSAGE:

ADULT	PEDIATRIC (<45 kg)
2 grams slow IV push.	15 mg/kg slow IV push.

DO NOT Exceed Adult Dose

PREGNANCY SAFETY: Category B- no proven risk to humans.

COMMENTS: Delayed effects can be seen up to 48 hours after administration consistent with anti-inflammatory actions.